Literature DB >> 8011565

High or low dose of angiotensin-converting enzyme inhibitor in patients with left ventricular dysfunction?

H Pouleur1.   

Abstract

Although it is widely accepted that angiotensin-converting enzyme inhibitors have become a cornerstone in the treatment of congestive heart failure, controversy still exists regarding the optimal doses of these drugs to use, and important variations in the daily dose used are seen among different physicians and countries. Nevertheless, objective data indicate that the efficacy of these drugs increases with dose and that most patients with heart failure tolerate the relatively high doses that have been used in large mortality trials. Presently, therefore, and unless new contradictory data become available, every effort should be made to use high doses of angiotensin-converting enzyme inhibitor in heart failure patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8011565     DOI: 10.1007/bf00877721

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  7 in total

1.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

Authors:  Salim Yusuf; Bertram Pitt; Clarence E Davis; William B Hood; Jay N Cohn
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

2.  A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

Authors:  J N Cohn; G Johnson; S Ziesche; F Cobb; G Francis; F Tristani; R Smith; W B Dunkman; H Loeb; M Wong
Journal:  N Engl J Med       Date:  1991-08-01       Impact factor: 91.245

3.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

Authors:  S Yusuf; C J Pepine; C Garces; H Pouleur; D Salem; J Kostis; C Benedict; M Rousseau; M Bourassa; B Pitt
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

4.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

5.  Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages.

Authors:  R Pacher; S Globits; J Bergler-Klein; H Teufelsbauer; M Wutte; W Baumgartner; E Ogris; D Glogar
Journal:  Eur Heart J       Date:  1993-02       Impact factor: 29.983

6.  Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

Authors: 
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

7.  Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

Authors:  S Yusuf; B Pitt; C E Davis; W B Hood; J N Cohn
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

  7 in total
  1 in total

1.  A survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure.

Authors:  R McMullan; B Silke
Journal:  Postgrad Med J       Date:  2001-12       Impact factor: 2.401

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.